Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis.

フォーマット:

論文

責任表示:

Takamura, Toshinari ; Shimizu, Akiko ; Komura, Takuya ; Ando, Hitoshi ; Zen, Yoh ; Minato, Hiroshi ; Matsushita, Eiki ; Kaneko, Shuichi

言語:

英語

出版情報:

日本内科学会, 2007-05-01

著者名:

Takamura, Toshinari

Shimizu, Akiko

Komura, Takuya

Ando, Hitoshi

Zen, Yoh

Minato, Hiroshi

Matsushita, Eiki

Kaneko, Shuichi

続きを見る

掲載情報:

Internal Medicine

ISSN:

1349-7235      

巻:

46

通号:

9

開始ページ:

579

終了ページ:

581

バージョン:

publisher

概要:

金沢大学大学院医学系研究科環境社会医学<br />A 53-year-old postmenopausal woman, who had a family history of cryptogenic liver cirrhosis, was diagnosed with osteoporosis, and started on the selective estrogen receptor modulator (SERM) raloxifene 60 mg/da … y orally. She developed marked liver dysfunction. Her body mass index (BNU) was 26.5. Her blood chemistry indicated AST 342 IU/L, ALT 356 IU/L, and hyaluronic acid 255 ng/mL. An oral glucose tolerance test showed impaired glucose tolerance with marked insulin resistance. Histologically, we diagnosed this case as having pre-cirrhotic nonalcoholic steatohepatitis (NASH). This is the first histologically confirmed case of NASH that was aggravated by raloxifene. © 2007 The Japanese Society of Internal Medicine. 続きを見る

URL:

http://hdl.handle.net/2297/6609